Legal professionals working in cosmetic corporations and law firms may be interested to know that the process of Cosmetic Product Registration and Listing under the mooted Cosmetic Registration and Listing Act (MoCRA) is inching closer to realization. One key development signaling this is the U.S. Food and Drug Administration (FDA) releasing a draft guidance document, providing more information regarding the newly required cosmetic product facility registrations and product listings to FDA.
The FDA’s Draft Guidance, clearly titled as Registration and Listing of Cosmetic Product Facilities and Products, offers the industry a comprehensive view on what to expect and prepare for in respect to the facility registrations and product listings. The document is a significant effort by the FDA to enhance transparency and encourage stakeholders’ feedback.
Being a draft document, the FDA has invited commentary from interested parties, as their input is critical in refining the guidance before its finalization.
While we wait for the final version to be release, this Draft Guidance can serve as a practical manual for those in the cosmetic industry, or those advising clients on navigating the new system. Its provisions could potentially shape the foundation for future regulations and protocols relating to Cosmetic Product Registration and Listing under MoCRA.
For a more exhaustive read and better understanding of the implications of the FDA’s Draft Guidance, consider reading the complete report by Beveridge & Diamond PC shedding light upon key takeaways such as implications and procedural aspects of the new Draft Guidance.